Cingulate Stock News
$3.87
6.75%
yesterday
Nasdaq,
Dec 16, 10:00 pm CET
Industry
Cingulate Stock News
Neutral
GlobeNewsWire
●
about 2 months ago
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control
Neutral
GlobeNewsWire
●
3 months ago
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval
Neutral
GlobeNewsWire
●
4 months ago
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026
Neutral
GlobeNewsWire
●
4 months ago
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
Neutral
GlobeNewsWire
●
4 months ago
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
